—
Coriolis Pharma, a biopharma company specializing in R&D and GMP drug product development, recently announced the launch of a new U.S. entity and two novel platform services designed to accelerate and de-risk the development of antibody drug candidates.
The new U.S. entity allows Coriolis to provide its clients with the convenience of a local presence while taking advantage of the company's international expertise. Following the launch, U.S. customers will have access to Coriolis' business development and client project management professionals, improving collaboration and support.
In addition to the new U.S. entity, Coriolis is also introducing two new platform services.
The first is the Developability Assessment Platform, which enables the selection of antibody candidates with optimal biophysical properties for successful drug product development. The service is particularly beneficial for projects with limited material availability and offers multiple pricing models to cater to small biotech startups and large pharmaceutical companies.
The second is the Systemic Antibody Pre-formulation Platform. This platform generates a comprehensive data set for holistic drug product development by systematically screening a broad formulation space of excipients. It assesses essential Quality Attributes (cQA) through accelerated stress testing, with the purpose of helping clients select the best lead formulations for subsequent stability studies and pre-clinical development.
These new platform services aim to mitigate risks and ensure that antibody drug candidates can be developed into commercial products in line with clients' Quality Target Product Profiles (QTPP).
“Because the U.S. will remain the center of innovation for biopharmaceuticals and cell and gene therapies, we believe it is critical to provide in-market project management, business development, and logistical support to our U.S. clients,” said Silvia Steyrer-Gruber, CEO of Coriolis. “The establishment of our U.S. entity opens the next chapter in expanding the global footprint of Coriolis.”
She continued: "We are committed to providing our clients with the highest quality services and supporting their drug development projects throughout the entire process."
Since their launch earlier this year, Coriolis' new offerings have already provided value to dozens of pharmaceutical companies and biotech startups looking to accelerate the development of antibody drug candidates. They combine the convenience of a local presence with the advantages of international expertise, supporting Coriolis’ mission to continue paving the way as a leading partner for drug product development in the U.S. market.
“Coriolis’ new science-driven developability assessment and pre-formulation screening offering signify the launch of a comprehensive program aimed at delivering advanced client-focused services,” said Coriolis CCO Johannes Clemens. “Engaging with Coriolis during the discovery and pre-clinical stages enable clients to accelerate time to market, reduce development risks, and proactively manage drug product development, ultimately increasing the valuation for licensing and M&A deals.”
About Us: Coriolis Pharma is a global service provider for R&D and GMP drug product development, R&D and GMP analytics, and sterile drug product manufacturing support. Coriolis offers a comprehensive range of services to support clients throughout the drug development process.
Contact Info:
Name: Jamie Bell
Email: Send Email
Organization: Coriolis
Website: https://www.coriolis-pharma.com/
Release ID: 89144293
Google
RSS